- |||||||||| alsevalimab (FPA150) / Amgen
Phase classification, Trial termination, Metastases: FPA150-001: FPA150 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Nov 22, 2024
P1, N=95, Terminated,
Phase classification: P1a/1b --> P1 | Completed --> Terminated; The Sponsor terminated the study for reasons unrelated to safety.
- |||||||||| alsevalimab (FPA150) / Amgen
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: FPA150-001: FPA150 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 11, 2022
P1a/1b, N=95, Completed,
Phase classification: P1a/1b --> P1 | Completed --> Terminated; The Sponsor terminated the study for reasons unrelated to safety. Active, not recruiting --> Completed | N=278 --> 95 | Trial completion date: Jan 2022 --> May 2021 | Trial primary completion date: Jan 2022 --> May 2021
- |||||||||| alsevalimab (FPA150) / Amgen
Trial completion date, Trial primary completion date, Metastases: FPA150-001: FPA150 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 3, 2021
P1a/1b, N=278, Active, not recruiting,
Active, not recruiting --> Completed | N=278 --> 95 | Trial completion date: Jan 2022 --> May 2021 | Trial primary completion date: Jan 2022 --> May 2021 Trial completion date: Jan 2024 --> Jan 2022 | Trial primary completion date: Jan 2023 --> Jan 2022
- |||||||||| alsevalimab (FPA150) / Amgen
Enrollment closed, Metastases: FPA150-001: FPA150 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 10, 2020
P1a/1b, N=278, Active, not recruiting,
Trial completion date: Jan 2024 --> Jan 2022 | Trial primary completion date: Jan 2023 --> Jan 2022 Recruiting --> Active, not recruiting
|
